Abstract
A series of thirty subjects with hyperlipemia selected among the out-patients with the chief complaint of hypertension, etc, were treated with clofibrate (C. P. I. B.; Amotril-Sumitomo) given at daily dosage of 6 to 12 capsules with average duration of 5.2 weeks. Clinical response of the patients to the treatment was as follows
a) An average decrease in serum total cholesterol of 57.2mg/100ml from a mean pre treatment level of 283.8mg/100ml was observed.
b) The patients also responded with an average decrease in serum triglycerides of 45.0mg/100ml from a mean pre-treatment level of 272.5mg/100ml.
c) We observed no evidence of significant alterations in the serum level cf uric acid.
Serum levels of unesterified fatty acids in normal adults following oral administration of the compound in a single dose of 25mg/kg indicate that, despite the conventional views, the compound produces no significant lowering of free fatty acid levels in the serum. The results thus implicate the mechanism whereby clofibrate effectively lowers the serum level of triglycerides involves not only inhibition of the free fatty acid utilization from the adipose tissue, but most probably some other ways of interference with the serum triglyceride level as well.
